BioLASCO Taiwan Co., Ltd. (TPEX:6662)
Taiwan · Delayed Price · Currency is TWD 29.75
+0.10 (0.34%)
At close: Feb 11, 2026
BioLASCO Taiwan Market Cap
BioLASCO Taiwan has a market cap or net worth of 761.96 million as of February 11, 2026. Its market cap has decreased by -15.96% in one year.
Market Cap
761.96M
Enterprise Value
734.66M
Revenue
277.12M
Ranking
n/a
PE Ratio
17.03
Stock Price
29.75
Market Cap Chart
Since January 4, 2018, BioLASCO Taiwan's market cap has decreased from 1.58B to 761.96M, a decrease of -51.80%. That is a compound annual growth rate of -8.61%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 10, 2026 | 759.40M | -4.35% |
| Dec 31, 2025 | 793.97M | -6.34% |
| Dec 31, 2024 | 847.76M | -0.30% |
| Dec 29, 2023 | 850.32M | 11.22% |
| Dec 30, 2022 | 764.52M | -1.97% |
| Dec 30, 2021 | 779.89M | -13.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Jan 4, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Lukas Biomedical | 1.19B |
| Holy Stone Healthcare | 1.13B |
| Neith | 1.08B |
| Level Biotechnology | 1.07B |
| TCI GENE | 1.01B |
| Taiwan Advance Bio-Pharmaceutical | 994.50M |
| Eusol Biotech | 985.03M |
| NatureWise Biotech & Medicals | 928.30M |